Key facts
| Recalling firm | Covidien, LP |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Surgipro II S8698GX SURGIPRO II BL 5/0 18 P-13 S8698GX |
| Classification | Class II |
| Recall number | Z-2922-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Product may contain a perforation or tear in the sterile barrier packaging. This issue may result in biocontamination of the sterile sutures, which may lead to infection, loss of vision if in ophthalmic utilization, or prolonged surgery. |
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Surgipro II S8698GX SURGIPRO II BL 5/0 18 P-13 S8698GX should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Covidien, LP. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Covidien, LP should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Covidien, LP directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Covidien, LP’s FDA history
Argus HQ has recorded 6 total FDA actions tied to Covidien, LP: 0 warning letters, 6 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Is Surgipro II S8698GX SURGIPRO II BL 5/0 18 P-13 S8698GX recalled?
- Yes. FDA lists a Class II recall by Covidien, LP for Surgipro II S8698GX SURGIPRO II BL 5/0 18 P-13 S8698GX, reported 20260819, with status "Ongoing." FDA recall number: Z-2922-2026.
- What is the recall class for Covidien, LP's recall?
- FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- Why was Surgipro II S8698GX SURGIPRO II BL 5/0 18 P-13 S8698GX recalled?
- FDA's recall record states the reason as: Product may contain a perforation or tear in the sterile barrier packaging. This issue may result in biocontamination of the sterile sutures, which may lead to infection, loss of vision if in ophthalmic utilization, or prolonged surgery.
- Who should I contact about this recall?
- Contact Covidien, LP directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Covidien, LP- Recall: Covidien, LP — Class II recall: Dermalon 88861757-31 DERMALON* 4-0 BLU 75CM C13 88861757-31 88861799-31… →
- Recall: Covidien, LP — Class II recall: V-Loc 90 Absorbable Wound Closure Device VLOC 90 0 VL 22 GS-21 VLOCM0336… →
- Recall: Covidien, LP — Class II recall: Surgipro SP-623 SURGIPRO* 2-0 BLU 75CM SC2 X36 SP-623 →
- Recall: Covidien, LP — Class II recall: V-Loc 180 Absorbable Wound Closure Device BOX BEDSIDE STAPLING IS KING BOX… →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Recall Database: Class II Recall: Surgipro II S8698GX SURGIPRO II BL 5/0 18… by Covidien, LP. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/covidien-lp-z-2922-2026-2026-08-19
"FDA Recall Database: Class II Recall: Surgipro II S8698GX SURGIPRO II BL 5/0 18… by Covidien, LP." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/covidien-lp-z-2922-2026-2026-08-19.
Argus HQ Research. "FDA Recall Database: Class II Recall: Surgipro II S8698GX SURGIPRO II BL 5/0 18… by Covidien, LP." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/recall/covidien-lp-z-2922-2026-2026-08-19.
@misc{argushq_argushq_ai_recall_covidien_lp_z_2922_2026_2026_08_19_2026,
title = {FDA Recall Database: Class II Recall: Surgipro II S8698GX SURGIPRO II BL 5/0 18… by Covidien, LP},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/covidien-lp-z-2922-2026-2026-08-19},
note = {Accessed: August 27, 2026}
}Source: FDA.gov — Recalls ↗

